Motivations: We seek to determine the accuracy of computational methods for predicting metabolic pathways in sequenced genomes, and to understand the contributions of both the prediction algorithms, and the reference pathway databases used by those algorithms, to the prediction accuracy.
Introduction
As more complete genomes are sequenced, the task of analyzing the resulting data looms ever larger. Automated analysis techniques can reduce the bottlenecks caused by human curators, and are vital for keeping up with the flood of sequence data. But how effective are they? For example, little is known about the accuracy of predicting the function of a protein via sequence-similarity methods, whether these methods are used in a manual or an automated fashion. Studies of the strengths and weaknesses of any particular algorithm are imperative, to identify the situations to which it can be usefully applied, and to estimate a level of confidence in the results it produces.
With the EcoCyc and MetaCyc projects (Karp et al., 2002b; Karp et al., 2002a) , our group has amassed a large, carefully curated collection of metabolic pathways from E. coli and other organisms, and has developed a sophisticated software environment for accessing and viewing information about each pathway and its component reactions, compounds, enzymes, etc. We developed the PathoLogic program to use EcoCyc and MetaCyc to predict the metabolic pathways of an organism from its annotated genome. PathoLogic takes as input an annotated genome sequence for an organism and produces a new Pathway/Genome Database (PGDB) containing those pathways that it has computationally inferred to be present in the organism. This paper evaluates the results of two recent improvements in our databases and algorithms, and also compares the use of our most sophisticated pathway-prediction program on the genome of H. pylori with a manual prediction of the pathways of H. pylori from its genome. More precisely, the comparisons we perform are as follows.
1. We compare two predictions of the pathway complements of H. pylori using our original PathoLogic algorithm: The first prediction, which we call HpyCyc-1, used the EcoCyc E. coli pathway database (DB) as the reference DB. The second prediction, which we call HpyCyc-2A, used the MetaCyc pathway DB (a superset of EcoCyc) as the reference pathway DB.
2. We compare two predictions of the pathway complement of H. pylori, using MetaCyc as the reference pathway DB, but using different algorithms. The first prediction used the original PathoLogic algorithm, and is the same as prediction HpyCyc-2A. The second prediction used an enhanced version of the algorithm -we call this prediction HpyCyc-2B. This enhanced version of the algorithm was developed as a result of our experiences in evaluation 1.
3. We compare prediction HpyCyc-2B with a manual prediction of the pathway complement of H. pylori by Marais et al. (Marais et al., 1999) 
The PathoLogic Algorithm
We begin with a description of the initial PathoLogic algorithm (Karp et al., 1999) , which is essential to understanding how the pathway prediction process works.
PathoLogic accepts two inputs: a fully annotated genome sequence, in Genbank file format, and a reference pathway DB (either EcoCyc or MetaCyc). Only the annotation information from the Genbank file is used by the program -PathoLogic does no sequence analysis. Specifically, the program uses the gene product names in the Genbank /product qualifier, and the EC numbers in the /ec number qualifier (when present).
The process of pathway prediction involves evaluating the evidence for the presence of each pathway in the reference DB for the organism being analyzed. A pathway consists of a sequence of enzyme-catalyzed reactions. The more enzymes within a pathway that are encoded by the genome, the more evidence we say there is for the presence of that pathway.
Link Enzymes to Reactions
In order to determine which enzymes encoded by the genome are associated with which pathways, PathoLogic performs a matching process between the enzyme names and Enzyme Commission (EC) numbers listed in the annotated genome, and the reaction steps listed in each pathway in its reference pathway DB. The matching process is based on the functions assigned to individual genes by the genome center that annotated the genome. We call this matching process "linking enzymes to reactions."
The motivations behind this process are as follows. (1) Reactions are the bridges between enzymes and pathways, in the sense that our pathway ontology (Karp and Paley, 1994) directly links a reaction to the pathways that contain it; once we know what reaction an enzyme catalyzes, it is trivial to retrieve the pathways containing that reaction. (2) Enzyme names are degenerate in the sense that the biomedical literature, and databases such as Swiss-Prot and Genbank, refer to a given enzymatic activity using many different names for the same activity, and occasionally, using the same name for different enzyme activities. (3) Enzyme names have low information content because by themselves they do not specify the precise biochemical activity of the enzyme. For example, the name "2-isopropylmalate synthase" tells us what product this enzyme can produce, but does not identify the reactants or the other products in this reaction. Until we know the full set of reactants and products for the enzyme (the reaction equation), we have only an approximate picture of its molecular function. In the course of our pathway prediction work we encounter many enzyme names in Genbank entries for which we cannot determine their reaction equations, even after exhaustive searches in Swiss-Prot (from which many enzyme names in Genbank entries for complete genomes are derived, based on sequence-similarity searches) and in Medline.
More precisely, linking enzymes to reactions means establishing a connection between the DB object that represents an enzyme, and a DB object that describes the reaction that enzyme catalyzes by listing its reactants and products.
The algorithm LinkEnzymesToReactions(names,ecnum) accepts as its inputs one or more gene-product names, and an EC number, from a single Genbank coding region. It returns up to two reactions as its outputs. The algorithm is as follows.
Match by EC Number:
If ecnum is non-null, retrieve from the MetaCyc DB the reaction identified by that EC number, and store that reaction in R 1 .
2. Build a hash table H whose entries associate enzyme names and reactions. The enzyme names in H are gathered from the Enzyme DB (Bairoch, 1996) In computing variant forms of E the program attempts to remove various extraneous text that is all too frequently found in Genbank /product fields (Karp, 2001 ), such as (1) Prefix and suffix words added to the enzyme name such as "putative," "probable," "alpha chain," "large subunit," etc. (2) Parenthesized gene names that follow the product name in some Genbank entries. This type of guesswork would not be required if gene product names were encoded using a controlled vocabulary such as the Gene Ontology (Ashburner et al., 2000) , or if EC numbers were used more frequently in Genbank entries -most genome annotations omit EC numbers.
We have found that 10-20% of the enzymes in a given genome are not identified by the preceding techniques because the names are not found in the hash table H. These enzymes are linked to their reactions manually by the PathoLogic user.
The only other potential information in the Genbank record that could aid in linking enzymes to reactions are gene names, and the sequence itself. Because we believe gene names are an ambiguous way to identify protein function, the program does not make use of gene names. Alternatively, we could have used sequence analysis to match protein sequences in the target organism with their counterparts of known function in EcoCyc (MetaCyc contains no sequence information). However, the field of fully automated functional assignment based on sequence analysis is a complex problem that is beyond the scope of this project, and we believe that the human annotators at most genome centers do a more reliable job of predicting function from sequence than does any existing automated algorithm.
Infer Pathways
Once the matching phase is complete, PathoLogic has inferred a set of reactions expected to occur in the target organism. Many of these reactions are components of pathways in the reference database. The remaining task is to determine which of those pathways are likely to be present in the target organism. Evidence for most or all of the reactions in a pathway constitutes strong evidence that the pathway is present in the organism. If there is evidence for some reactions in a pathway but not others, there are three possible interpretations:
• The pathway is not present in the target organism (either the reactions for which there is evidence are being used for some other purpose, these genes are not expressed, or their functions were predicted incorrectly from sequence).
• A variant form of the pathway is present in the target organism that uses some but not all of the steps from the pathway, as described in the reference database.
• The pathway is present in the target organism, but the genes for the missing reaction steps either have not been found by the name-matcher or have not yet been identified in the genome. An enzyme E that catalyzes reaction R might not have been identified in the genome because the sequence of E has diverged so far from the sequences of other known enzymes that catalyze R that the homology cannot be detected, or because E is not evolutionarily related to other sequenced enzymes that catalyze R.
It is not easy to determine which of these three interpretations is the correct one. The initial PathoLogic algorithm errs on the liberal side of predicting more pathways by assuming that a pathway can be present in the target organism if there is evidence for at least one of its reactions (with one exception: MetaCyc contains a number of sets of specifically marked variant pathways. If there is more evidence for one member of a variant set than for the others, then only that variant is assumed to be present in the target organism). Although a great many pathways are therefore considered potentially present, the measure of the likelihood of a pathway actually being present in the organism is based on the proportion of reactions in the pathway for which there is evidence, and the presence of "unique" reactions; i.e., evidence for a reaction that occurs only in one pathway is stronger evidence for that pathway than evidence for a reaction that occurs in several other pathways as well.
PathoLogic is intended to provide a first-pass pathway analysis -it is not expected to replace manual curation;, rather, it provides a solid stepping-off point to make manual analysis as quick and straightforward as possible.
Results: Comparison of HpyCyc-1 with HpyCyc-2A
The first PGDB for H. pylori (HpyCyc-1) was generated in 1997 with an early version of the PathoLogic software and using EcoCyc as the reference database. The annotated H. pylori sequence dataset was an early version that existed before the version deposited in Genbank by The Institute for Genomic Research (TIGR). The gene-to-reaction mapping for HpyCyc-1 was not performed by PathoLogic, but was provided directly by personnel at TIGR in personal correspondence with Dr. Karp prior to the publication of the complete genome sequence, and Table 1 : A summary of pathway predictions for H. pylori, using EcoCyc and MetaCyc as the reference DBs to produce HpyCyc-1 and HpyCyc-2A, respectively. Note that the difference in the number of gene and reaction matches between the two PGDBs is not due to any inherent properties of the reference databases, but rather to the different methods used to generate the matches.
was supplemented to a limited extent by additional SRI analyses. The resulting PGDB was subject to a small amount of manual correction and enhancement.
The MetaCyc database, created in 1998, contains 130 pathways from EcoCyc, and another 230 metabolic pathways from over 130 different organisms. The pathways in MetaCyc were gathered from a number of literature and online sources. When EcoCyc is used as a reference database for PathoLogic, the only pathways that can be inferred are those that are shared between the target organism and E. coli. We expected that, by using MetaCyc as the reference database, PathoLogic would be able to infer additional pathways that are not found in E. coli and, to some extent, would be able to distinguish between variants of a pathway that are found in different organisms.
For this study we created a second PGDB (HpyCyc-2A) for H. pylori, using the version of PathoLogic described in the Methods Section. This PGDB was generated from the complete annotated Genbank sequence entry for H. pylori (AE000511 (Tomb et al., 1997) ), with MetaCyc used as the reference database. Most of the PathoLogic processing is automated, but a number of the enzyme names in the Genbank record were not recognized by the PathoLogic enzyme-name matcher. We therefore performed manual matching of enzyme names to EC numbers for approximately 10% of the metabolic enzymes in H. pylori. Table 1 summarizes the relevant contents of the resulting PGDBs.
With MetaCyc as the reference database, 135 pathways were predicted (i.e., evidence was found for at least one reaction in all these pathways), as opposed to 77 pathways when EcoCyc was used as the reference database. This confirmed our hypothesis that MetaCyc would infer in more pathways than EcoCyc.
Closer examination, however, showed that many of the predicted pathways were false-positive pathways -pathways that were highly unlikely to be present, based on other biological knowledge. For example, in many pathways there was evidence for only a single reaction that was also present in many other pathways; therefore, that reaction could not be considered strongly indicative of any particular pathway. Nonetheless, at least 10 of the new pathways represent significant additions. Some of these new pathways happened to be E. coli pathways that had been added to both EcoCyc and MetaCyc after 1997, when HpyCyc-1 was created. Predicted pathways whose origin in MetaCyc was from organisms other than E. coli included an arginase degradation pathway, a UDP-glucose conversion pathway, a glutamine biosynthesis pathway, and an aerobic glycerol fermentation pathway. A small number of variant pathways were inferred by PathoLogic in place of the original E. coli pathways. An example is a polyamine biosynthesis pathway from Bacillus subtilis that formed a subset of the original E. coli pathway.
There are only a few cases where a pathway P was inferred in HpyCyc-1, but neither P nor any of its variants were inferred in HpyCyc-2A. These pathways were due to genes that our namematching algorithm failed to match to any reaction in the pathway, but that were matched to such reactions in HpyCyc-1 (such matches were either supplied by TIGR or were results of SRI's analysis). Perusal of the corresponding entries in the Genbank file showed that either no enzyme name was present in these cases or only one enzyme name, whereas the enzyme was presumed to be multifunctional in the original PGDB. For example, an aspartate biosynthesis pathway consisting of a single reaction, EC number 2.6.1.1, was inferred in HpyCyc-1, but not in HpyCyc-2A. The original PGDB linked this reaction to HP0624, based on sequence similarity to the aspB gene in B. subtilis, but the enzyme name "aspartate aminotransferase" does not appear in the Genbank entry. Rather, the product for this gene is described as "solute-binding signature and mitochondrial signature protein (aspB)," which would indicate that this gene product does not carry out the aspartate aminotransferase reaction. It is not clear whether the sequence annotation is incomplete or whether the gene was incorrectly matched to a reaction in HpyCyc-1.
Results: Comparison of HpyCyc-2A to HpyCyc-2B
Because a significant number of probable false-positive pathways existed in the MetaCyc-based prediction (HpyCyc-2A), we explored heuristics for identifying these false-positive predictions. It was impossible to eliminate all undesirable pathways while still keeping all those that we believed should be kept. For example, a significant fraction of reactions from the Calvin Cycle are present in H. pylori, although none of those reactions are unique to the Calvin Cycle. But since H. pylori is not a photosynthetic organism, that pathway is highly unlikely to be present in the organism in any form. We created a new version of PathoLogic called PathoLogic-2, containing an algorithm that identifies false-positive pathways. The algorithm singles out for deletion the pathways that meet the following heuristic criteria:
• The pathway contained evidence for no unique enzyme, AND
• Either -The pathway consisted of more than two reactions but contained evidence for only a single reaction, OR -The set of reactions for which there was evidence was a proper subset of the set of reactions for which there was evidence in some other pathway, AND one of the following was true: * The pathway was classified as a biosynthetic pathway and was missing one or more steps from the end of the pathway. The rationale for this criterion is that if the final steps are missing, then the pathway is not producing its intended target, so the other pathway(s) containing the common reactions are more likely to reflect the actual role of those reactions in the organism. * The pathway was classified as a degradation pathway and was missing one or more steps from its beginning. The rationale for this criterion is that if the initial steps are missing, then the pathway is not degrading its intended substrate, so the other pathway(s) containing the common reactions are more likely to reflect the actual role of those reactions in the organism. * The pathway was classified as an energy metabolism pathway and was missing at least half its reactions. The rationale for this criterion is that there is a great deal of overlap of reactions among the energy metabolism, with many reactions appearing in many pathways. Thus, many false positives are likely to be inferred from among these pathways. An arbitrary but reasonable cutoff for excluding some of these false positives is 50%.
We ran the enhanced PathoLogic-2 program to create a new MetaCyc-based pathway prediction for H. pylori, called HpyCyc-2B. HpyCyc-2B is available through the WWW at URL http://ecocyc.org:1555/HPY/organism-summary?object=HPY. HpyCyc-2B contains 98 pathways, which is almost 30% fewer pathways than does HpyCyc-2A, and the enhanced algorithm removes only pathways that we believe to be false-positive predictions. For example, an arabinose catabolism pathway was pruned because the only reaction in the pathway for which there was any evidence was the conversion of ribulose-5-phosphate to xylulose-5-phosphate, which also appears in the pentose phosphate pathway and elsewhere. A 2-dehydro-D-gluconate pyruvate catabolism pathway was pruned because this was a degradative pathway missing its initial two reactions, and the six reactions for which there was evidence were all part of the glycolysis/Entner-Doudoroff super-pathway.
Results: Comparison of HpyCyc-2B with Manual Pathway Analysis of H. pylori
We compared the HpyCyc-2B prediction created by PathoLogic-2 with a recent review article that analyzes the principal metabolic pathways of H. pylori by combining experimental biochemical analyses of H. pylori with data derived from the whole genome sequence (Marais et al., 1999) . Thus, we can critique our computational methods by seeing how well their predictions compare to a manual genome analysis, as well as against experimental data. This critique is necessarily incomplete, because the review article selects only a subset of metabolism to analyze and does not provide details in all cases, and PathoLogic's predictions are confined to the enzymes of small molecule metabolism (for example, PathoLogic does not consider transport processes, but the review does). Note that PathoLogic does not make use of the same biochemical analyses that Marais et al. did, putting the program at somewhat of a disadvantage from the start.
In general, PathoLogic found most of the pathways that the article claims are present, but it often did not find matches in the genome for as many of the reaction steps as did Marais et al. There were a few pathways that PathoLogic did not find at all. There are several reasons why PathoLogic missed reaction steps. In a number of cases, only a single reaction was ascribed to a gene known to be multifunctional (since in general only a single function is listed for each gene in the Genbank file). In other cases, the Genbank entry for a gene did not contain the information necessary for PathoLogic's name-matching routine to link the gene to any reaction. In still other cases, the usual enzyme for a particular step was not present, but another enzyme (with a different name) could be used to perform the same task. Marais et al. were able to identify such cases, but PathoLogic could not.
Although PathoLogic inferred many pathways that were not mentioned by the article, it did not infer any pathways that the article specifically said were missing. Pathways that the article claimed were incomplete were typically inferred by PathoLogic, but without evidence for the steps that Marais et al. did not find.
Detailed Comparison of HpyCyc-2B with Review by Marais et al.
This section provides a detailed comparison of HpyCyc-2B with each relevant section of the review article.
Glucose Metabolism
According to the review, glucose appears to be the only carbohydrate used by the organism. Although PathoLogic's initial analysis did show several other carbohydrate catabolism pathways, almost all fall into the category of false-positive pathways and were removed. The only remaining carbohydrate catabolism pathways are glycerol catabolism and a pathway that combines galactose, galactoside, and glucose catabolism.
The Entner-Doudoroff pathway is known to be present in H. pylori, as are both oxidative and nonoxidative parts of the pentose phosphate pathway (though with one gene not yet identified); glycolysis and gluconeogenesis are very likely present, although not all the genes have been identified. The PathoLogic predictions bear this out, with all five pathways inferred, but with the indicated steps missing from glycolysis and the pentose phosphate pathway.
Pyruvate Metabolism
The review describes a 3-step pathway from pyruvate to acetate. MetaCyc does not contain this pathway, but includes the conversion of pyruvate to acetate as one branch of a larger propionate fermentation pathway that was inferred. PathoLogic found evidence for only two of the three relevant steps. The gene they identify for the other step has no product name listed in the Genbank entry (the entry does contain a note identifying the gene as a putative acetate kinase). PathoLogic did identify genes for the other transformations of pyruvate that are mentioned in the article.
The TCA Cycle
In place of the normal Krebs or Tricarboxylic Acid (TCA) Cycle, H. pylori appears to use a branched noncyclic pathway. This reductive citric acid pathway was entered into HpyCyc-1 manually, and was subsequently copied into MetaCyc. We would therefore expect that this variant pathway would be inferred to be present in the new PGDB, rather than the TCA Cycle. This is in fact what happened. Some of the genes involved in this pathway have not yet been identified, but PathoLogic was able to match up the genes for all the other steps.
Amino Acid Metabolism
The review states that H. pylori requires arginine, histidine, isoleucine, leucine, methionine, phenylalanine, and valine for growth, but can synthesize all other amino acids. In accord with the observations of the review, PathoLogic does not infer any pathways for arginine, histidine, or phenylalanine biosynthesis, and infers only partial pathways for isoleucine, leucine, methionine, and valine. PathoLogic infers complete biosynthetic pathways for threonine, tryptophan, serine, glycine, glutamine, glutamate, lysine, cysteine, and chorismate. It does not infer any pathway for aspartate or asparagine biosynthesis (the failure to assign the aspB gene to the aspartate transaminase reaction is discussed in the section comparing HpyCyc-1 with HpyCyc-2A). PathoLogic inferred only partial pathways for tyrosine, alanine and proline biosynthesis. In the case of tyrosine biosynthesis, the review states that the tyrB gene is missing, but that another enzyme can perform its function (we did not link that enzyme to this reaction). Also, the tyrA gene should catalyze two reactions in this pathway, but we linked it only to the one function mentioned in the Genbank file. These results point out the difficulty of distinguishing between partially inferred pathways in which steps are actually missing from the organism and. those in which the steps are present but have not been identified by our algorithm.
The review cites experimental and genomic evidence for the catabolism of alanine, arginine, aspartate, asparagine, glutamate, glutamine, and serine. It did not mention evidence for catabolism of any other amino acids: presumably none was found. PathoLogic inferred complete pathways for catabolism of alanine, glutamate and serine, and partial pathways for catabolism of arginine and asparagine. It did not find any pathways for aspartate or glutamine catabolism (although there are reactions that interconvert glutamine and glutamate, and asparagine and aspartate, specific pathways are probably not necessary). It also found a partial proline degradation pathway and single reactions within pathways for the degradation of methionine, threonine, and leucine. Pathways for the degradation of glycine, isoleucine, and valine were originally inferred, but were later classified as false-positive pathways, in agreement with the review.
Lipid Metabolism
PathoLogic found most of the fatty acid degradation pathways, and all but one reaction from the fatty acid synthesis pathways (initiation and elongation). According to the review, phospholipid degradation has been observed experimentally, but the corresponding genes have not been found. PathoLogic did not infer a phospholipid degradation pathway. The phospholipid biosynthesis pathway presented in the review forms a subset of the corresponding pathway that was inferred from MetaCyc; our software inferred all but one of the steps that were identified in the review.
Lipopolysaccharide Biosynthesis
PathoLogic found evidence for almost every step in lipid-A and (KDO)-lipid-A biosynthesis. It did not infer any steps from O-antigen biosynthesis (from E. coli), although the review mentions two enzymes that are possibly present. PathoLogic inferred the enterobacterial common antigen synthesis pathway on the basis of a single step catalyzed by fucosyltransferase, though there are different kinds of fucosyltransferases and it appears that in this case PathoLogic may have linked the polypeptides to the wrong reaction.
Nucleotide Biosynthesis
PathoLogic inferred complete pathways for the synthesis of PRPP and UMP.
According to the review, although H. pylori is known experimentally to be able to synthesize IMP from PRPP, evidence for only two of the ten relevant enzymes has been found in the genome. Similarly with that, our software identified only two steps along the path to IMP in the purine biosynthesis pathway. The remainder of that pathway, which synthesizes GMP and AMP from IMP, is complete, as indicated by the review. Phosphorylation to GTP and ADP in our PGDB is part of another, larger nucleotide metabolism pathway: all relevant steps are inferred by PathoLogic. The review states that guanylate kinase activity has not been observed experimentally and speculates that the corresponding gene may not be expressed normally, and that the syntheses of GTP and ITP may follow an alternative unknown pathway instead. If true, this would be an example of genomic data leading PathoLogic to make incorrect inferences, since PathoLogic has no way of determining which genes are not expressed.
The review states that H. pylori has limited pyrimidine salvage capability, but active purine salvage pathways. Uracil metabolism has been observed experimentally, but the gene has not been identified. That step is part of our larger pyrimidine ribonucleotide/ribonucleoside metabolism pathway, and is accordingly not inferred. The metabolism of adenine, guanine and hypoxanthine, part of our larger nucleotide metabolism pathway, are all completely inferred.
The synthesis of deoxyribonucleotides and other interconversions among them were all inferred (some as part of a larger deoxypyrimidine nucleotide/side metabolism pathway), to the extent that they are identified in the review article.
Respiratory Chains
In MetaCyc, there is no complete respiratory chain pathway. Rather, three "pathways" collections of reactions involving electron donors (for anaerobic and aerobic respiration) and electron acceptors (for anaerobic respiration). The electron acceptors pathway and the aerobic respiration electron donors pathway were inferred. The anaerobic electron donors pathway was inferred in HpyCyc-2A, but was subsequently classified as a false-positive pathway, because the only reactions PathoLogic identified for it were shared by both electron donor pathways, and the name matcher failed to find the match from the quinone-reactive Ni/Fe hydrogenase protein to the hydrogenase reaction.
The ubiquinone biosynthesis and polyisoprenoid biosynthesis pathways are both inferred from the presence of the three genes referenced in the review article. The menaquinone biosynthesis pathway is not inferred. Although the review article states that menaquinones are experimentally known to be present in H. pylori, it does not cite any genomic evidence.
Catalase and Superoxide Dismutase
The pathway for the removal of superoxide radicals, which consists of superoxide dismutase and catalase was completely inferred by PathoLogic, in agreement with the review article.
Nitrogen Sources
According to the review, H. pylori uses urea, ammonia, and amino acids as nitrogen sources. Our results are entirely consistent with that analysis. Amino acid metabolism was addressed in a previous section. Ammonia is incorporated via a glutamine biosynthesis pathway that matches the one shown in the review (though the version in the review looks somewhat different). The urease genes were matched to the appropriate reaction, which is the only step inferred in a ureide degradation pathway.
Discussion
On the whole, the HpyCyc-2B results match well with the analysis in the review article.
Since our enzyme-to-reaction matching procedure is fairly conservative, we did not expect it to make many incorrect matches (which would cause pathways to be inferred that were known to be missing), but due to incomplete annotation and the lack of uniformity in product names in the Genbank file, we anticipated that the program would fail to link some genes to their reactions. The Genbank file for H. pylori contains few or no EC numbers, so the only way our program can link enzymes to reactions is by matching enzyme names. The approximately 10% of the enzyme names that had to be matched manually may sound like a large group, but this task is not as onerous as it sounds. Since PathoLogic extracts from the total list of unmatched genes only those that are probable enzymes, it is relatively simple to run down that list and determine those that are likely to match reactions. Rather, we think it is a significant achievement that so many genes can be matched correctly to reactions with no manual intervention. Table 2 divides the list of pathways that PathoLogic inferred (or failed to infer) into several categories:
• Consistent: Pathways that were inferred or partially inferred in a manner consistent with the description of genomic evidence in the review article. We included in this category MetaCyc pathways predicted to be present but for which some smaller branch of the pathway is probably absent.
• Partially consistent: Pathways that are partially consistent with the description in the review article but are missing some steps that should have been found (i.e., the review article says the genomic evidence for those steps is present).
• Poor topological match: Pathways for which some steps were correctly inferred but whose topology does not match pathways described in the review.
• Not reported: Pathways inferred by PathoLogic but not addressed in the review article (for example, the review article did not discuss many cofactor biosynthesis pathways that are undoubtedly present in the organism). We believe these are correct PathoLogic predictions for pathways whose presence were overlooked by Marais et al.
• False positive: Pathways inferred by PathoLogic that are probably not present in the organism.
• Missing: Pathways described by the review that were not inferred by PathoLogic (or, in one case, inferred based on incorrect information).
Note that the distinctions between some of these categories are not always clearcut, in part because the definition of what forms a pathway is not standardized, and in part because the review does not completely specify many of the pathways. Also, it is difficult to judge whether a pathway that is not mentioned in the review is in fact missing from the organism.
By switching from using EcoCyc to using MetaCyc as the reference database, we hoped to expand the range of pathways that we could predict. We also hoped that with more pathway variants defined, we would be better able to select the correct sequence of reactions from among several similar alternatives, and that therefore holes in pathways could be more reliably attributed to missing gene assignments (or nonfunctional pathways in the organism). The PathoLogic-2 predictions have certainly expanded to cover aspects of metabolism not seen in E. coli (though not to a large extent, probably because E. coli and H. pylori are fairly closely related). It is unclear whether the frequent pathway holes in the predicted pathways are due to enzymes that will later be identified in the genome, or are due to pathway variants that do not exist in MetaCyc.
Although we anticipated that PathoLogic would infer a number of pathways (generally with low evidence scores) that were not actually present in the organism, we did not expect quite as glycolysis many of these as were observed in HpyCyc-2A. Nor did we anticipate how much of a distraction these false-positive pathways would be to a user trying to make sense of the resulting PGDB as a whole. The PathoLogic-2 algorithm for weeding out such pathways and producing HpyCyc-2B, while conservative (because we did not want to risk discarding important pathways), will add significantly to the comprehensibility of the PGDBs that PathoLogic generates.
Comparison with Other Pathway Prediction Algorithms
We were interested to see whether other available metabolic reconstruction systems such as KEGG (Goto et al., 1997; Bono et al., 1998) and WIT (Selkov et al., 1997) were able to avoid the problems we encountered in attempting to predict pathways that should be present while avoiding false-positive pathway prediction. Although we did not perform an exhaustive analysis of the contents of other pathway databases, a sample of comparisons suggests the other projects make significant numbers of false-positive predictions. Comparisons are hampered by two factors. First is that neither of these projects have published precise descriptions of their pathway-prediction algorithms.
The second is that although the KEGG developers state that they use EC numbers to match enzymes to pathways (Bono et al., 1998) , this description is probably incomplete because many KEGG pathway maps contain enzymes that do not have EC numbers, and KEGG highlights those enzymatic steps as occurring in certain species. In addition, the KEGG system does not actually make pathway predictions. The KEGG system simply highlights, on a WWW page describing a pathway map, which set of reactions in that map are present in a selected organism. KEGG does not actually make a decision as to whether the pathway is present in the organism or not: every possible pathway is available for every organism. The user must decide whether a pathway is present and, as we have seen, that decision is not an easy one because false-positive evidence often exists for many pathways. For example, the KEGG pathway maps show evidence for two large photosynthetic pathways in H. pylori (PathoLogic-2 predicts no photosynthetic pathways), despite the low probability of such a pathway being present in the organism.
In the case of WIT, it is not even clear if the pathway prediction process is automated or manual. WIT does seem to be much more selective in its pathway predictions. It did not predict any obviously incorrect photosynthetic pathways for H. pylori. However, it also failed to predict such pathways as glycolysis or the Entner-Doudoroff pathway, both of which are almost certainly present (Marais et al., 1999) .
Conclusions
This study validates the usefulness of PathoLogic as a tool for metabolic analysis of an organism's annotated genome. If the reference pathway DB used by PathoLogic from the EcoCyc DB is expanded to the larger MetaCyc DB, the number of true positive pathways predicted in H. pylori increases. In addition, the number of false-positive predictions increases. False-positive predictions can be decreased by means of the scoring heuristics in the PathoLogic-2 algorithm, which give preference to pathways containing enzymes that are not used in other pathways in the organism. The study also shows that computational pathway analysis by PathoLogic-2 produces results that have accuracy comparable to that of analyses by expert biochemists, but that exceed the expert analyses in comprehensiveness.
Furthermore, the generation of HpyCyc requires only a few hours of manual effort and computer processing. The result of the computational analysis is not just a set of predictions, but also a sophisticated software environment for exploring and building on those predictions. Some manual polishing is required in order to make the generated PGDB truly reflective of the organism it describes, but the PGDB generated by PathoLogic provides a valuable and accurate foundation to support further metabolic research.
